Clinical trial
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive…
NCT00422981 · Allon Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00422981 |
|---|---|
| Title | Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment |
| Official title | A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Effect on Cognitive Function of AL-108 After 12 Weeks of Intranasal Administration in Subjects With Mild Cognitive Impairment |
| Lead sponsor | Allon Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mild Cognitive Impairment, So Stated |
| Intervention type | Drug |
| Interventions | AL-108, Placebo |
| Enrollment | 144 |
| Start date | Jan 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Jan 17, 2007 |
| Last update posted | Oct 24, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: